港股異動 | 赤子城科技(9911.HK)大漲逾12%破頂 市值首次突破百億港元
格隆匯2月16日丨赤子城科技(9911.HK)延續強勢行情,現拉昇至12.13%,高見10.42港元再次刷新歷史高價,總市值首次突破百億港元大關。赤子城科技近期利好消息不斷。App Annie此前發佈“2021 Level Up年度發行商大獎”,赤子城科技旗下MICO憑藉在社交出海市場的快速增長,成功入選“2021年度中國廠商出海收入飛躍榜”,排名第14位。 此外,赤子城科技曾於1月28日發公吿稱2020年總收入預增150%-250%。另外,該公司指,未來會拓展“流量+社交”的模式,亦會探索在電商方面的可能性,包括直播帶貨、跨境電商、線上營銷等與社交產品結合的嘗試。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.